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The mitogen-activated protein kinases are key regu-
lators of cellular organization and function. To under-
stand the mechanisms(s) by which these ubiquitous ki-
nases affect specific cellular changes, it is necessary to
identify their diverse and numerous substrates in dif-
ferent cell contexts and compartments. As a first step in
achieving this goal, we engineered a mutant ERK2 in
which a bulky amino acid residue in the ATP binding
site (glutamine 103) is changed to glycine, allowing this
mutant to utilize an analog of ATP (cyclopentyl ATP)
that cannot be used by wild-type ERK2 or other cellular
kinases. The mutation did not inhibit ERK2 kinase ac-
tivity or substrate specificity in vitro or in vivo. This
method allowed us to detect only ERK2-specific phos-
phorylations within a mixture of proteins. Using this
ERK2 mutant/analog pair to phosphorylate ERK2-asso-
ciated proteins in COS-1 cells, we identified the ubiq-
uitin ligase EDD (E3 identified by differential display)
and the nucleoporin Tpr (translocated promoter region)
as two novel substrates of ERK2, in addition to the
known ERK2 substrate Rsk1. To further validate the
method, we present data that confirm that ERK2 phos-
phorylates EDD in vitro and in vivo. These results not
only identify two novel ERK2 substrates but also pro-
vide a framework for the future identification of numer-
ous cellular targets of this important signaling cascade.
The mitogen-activated protein kinase (MAPK)1 or extracel-
lular signal-regulated kinase (ERK) pathway is an evolution-
arily conserved signaling pathway that regulates many cellular
processes, including proliferation, differentiation, gene tran-
scription, and cellular migration (1). Activation of the Ras
oncogene stimulates the membrane recruitment and activation
of the Raf protein kinases (2–4), which in turn phosphorylate
and activate MAPK kinase or ERK kinases (MEK) 1 and 2.
These in turn phosphorylate and activate ERK1 and ERK2 (5).
When in the inactive state, ERKs are anchored in the cyto-
plasm due to a basal association with the MEKs. Following
activation, the ERKs migrate to various cellular locations, in-
cluding the nucleus, microtubules, focal contacts, and others
(6–9) where they phosphorylate a variety of substrates. These
diverse phosphorylations allow the ERKs to orchestrate a com-
plex but coordinated response to extracellular signals. The
pattern and timing of substrate selections determines the spe-
cific biological outcome.
The identification and characterization of the direct targets
of a particular signaling pathway is paramount to understand-
ing the function of that pathway within the cell. The Ras to
ERK pathway is a key regulator of many cellular processes.
Although there are many substrates of the ERKs that have
been identified (10, 11), the diverse roles of the ERKs within
the cell suggest that many unknown substrates remain to be
identified. Identification of the kinase that directly phosphoryl-
ates a particular substrate can be difficult due to the overlap of
consensus phosphorylation sequences, redundancy of kinases
that can phosphorylate a particular site, differences between in
vivo and in vitro specificity, and the diversity of kinases that
can be present in a reaction, even in “pure” protein prepara-
tions. Several different approaches to determine novel MAPK
substrates have been used (12). These include two-hybrid anal-
ysis (13, 14), proteomic approaches under conditions of ERK
activation (11), phosphorylation of column fractions from cells
(15), and a solid phase phosphorylation assay (16).
To identify additional novel substrates of ERK2, we em-
ployed a method developed by Shokat and coworkers (17, 18) to
specifically label direct substrates of a particular protein ki-
nase in a mixture of cellular proteins. Protein kinases contain
similar ATP binding domains, including conserved residues
that come into close contact with the N-6 position of ATP.
Mutation of the ATP binding site at one or both of these
conserved positions to a smaller amino acid residue can allow
the mutant protein kinase, but not other cellular protein ki-
nases, to utilize analogs of ATP that contain a bulky substitu-
ent on the N-6 position. When radiolabeled ATP analog is used
in a kinase reaction with the mutant kinase and a mixture of
cellular proteins, only direct substrates of the mutant kinase
become radiolabeled. This method has been successfully used
to identify direct substrates for the Src tyrosine kinase (19) and
for the MAPK JNK (20).
We used an engineered mutant of ERK2 to search for new
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ERK substrates that physically associate with the MAPK. As
validation of our method, our assay resulted in the labeling and
identification of Rsk1, a known ERK2 substrate (7). We also
identified two novel ERK2 substrates, the ubiquitin ligase EDD
(E3 identified by differential display) and the nucleoporin Tpr
(translocated promoter region). EDD is the human homolog of
the Drosophila gene hyperplastic discs and was originally iden-
tified as a gene up-regulated in response to progestin (21). EDD
is believed to serve as an E3 ubiquitin ligase due to the pres-
ence of a HECT domain (homology to E6-AP carboxyl terminus)
in its carboxyl terminus that binds ubiquitin through a single
cysteine residue (21). Honda et al. (22) have identified the
topoisomerase II beta binding protein TopBP1 as a ubiquitina-
tion target of EDD. Tpr is a nucleoporin that is a component of
the nuclear basket of the nuclear pore complex (23, 24). Func-
tional studies suggest a role for Tpr in the nuclear export of
proteins with a nuclear export signal (25).
In this report we describe the engineering of ERK2 to allow
it to utilize an analog of ATP. Based on sequence alignment of
ERK2 with other protein kinases and the crystal structure of
ERK2, we generated alanine and glycine mutations of ERK2 at
isoleucine 82 and glutamine 103, singly or in combination, to
generate an ERK2 with a larger ATP binding pocket. Mutation
of these residues did not significantly inhibit ERK2 kinase
activity in vitro or signaling in vivo. ERK2 mutants with a
glutamine to glycine mutation at position 103 were able to
efficiently utilize several ATP analogs to phosphorylate the
ERK substrate Elk1 (26) in vitro. Using ERK2 Q103G and
[-32P]cyclopentyl-ATP, we were able to radiolabel EDD, Tpr,
and Rsk1 as ERK2-associated substrates in COS-1 cells. We
further validated these results by demonstrating that EDD was
phosphorylated by ERK2 in vitro and in an MEK-dependent
manner in cells in response to EGF. This work describes the
generation of a molecular tool for the identification of many
more targets of this important signaling cascade.
EXPERIMENTAL PROCEDURES
Cell Culture and Plasmids—COS-1 cells were purchased from Amer-
ican Type Culture Collection (ATCC, Manassas, VA). COS-1 cells were
grown in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad,
CA) and 10% fetal bovine serum (Invitrogen). FLAG-ERK2 has been
described previously (27). FLAG-ERK2 mutants were generated using
the Transformer mutagenesis kit (Clontech, Palo Alto, CA). Transfec-
tions were performed using LipofectAMINE (Invitrogen) according to
the manufacturer’s recommendations. A plasmid for expression of ami-
no-terminal FLAG-tagged EDD was constructed by cloning full-length
EDD from pBluescript EDD (21) into the pCMV-Tag2B vector (Strat-
agene, La Jolla, CA).
Luciferase Assays—COS-1 cells were transfected in duplicate with 1
g of 5 GAL4-luciferase; 50 ng of GAL4-Elk1 (28); 100 ng of MEK1
S218D/S222D; and 5, 25, or 100 ng of ERK2 plasmid. DNA amounts
were brought up to 2 g of total DNA with empty vector. The cells were
incubated in serum-free media overnight and harvested at 24 h. Lucif-
erase activity was determined on a Monolight 2010 Luminometer (An-
alytical Luminescence, Ann Arbor, MI).
Analog Inhibition Assays and Elk1 Phosphorylation—FLAG-ERK2
plasmids were transfected into COS-1 cells using LipofectAMINE (In-
vitrogen). The cells were later serum-starved for 4 h before stimulation
with 10 ng/ml EGF (Upstate Biotechnology, Lake Placid, NY) for 10
min. The cells were harvested in FLAG lysis buffer (27) and FLAG-
ERKs immunoprecipitated with M2 anti-FLAG-agarose (Sigma, St.
Louis, MO). The immunoprecipitates were washed three times in lysis
buffer and twice in kinase buffer (25 mM HEPES, pH 7.4, 10 mM
magnesium acetate, and 1 mM dithiothreitol). For analog inhibition
assays, duplicate reactions containing 20 g of myelin basic protein
(MBP), 10 M ATP, 10 Ci/reaction [-32P]ATP (6000 Ci/mmol,
PerkinElmer Life Sciences, Boston, MA), and either buffer control or
100 M ATP analog. The reactions were incubated at 30 °C for 10 min,
resolved on a gel, and transferred to nitrocellulose. MBP bands were
excised and quantitated by Cerenkov counting. Each value was com-
pared with the mean of the control reactions (no analog), averaged with
its duplicate, and graphed as a percentage of the control, which was set
to 100%. For Elk1 phosphorylation, the immunoprecipitated ERKs were
mixed with 1 g of GST-Elk1 and either 100 M ATP or 100 M ATP
analog. The reactions were incubated at 30 °C for 10 min, resolved on a
gel, and immunoblotted with anti-phospho-S383 Elk1 antibodies (New
England BioLabs, Beverly, MA).
32P-Labeling of Cyclopentyl ADP (cpADP)—Nucleoside diphosphate
kinase (NDPK, 200 units, Sigma) and 800 Ci of [-32P]ATP were added
in a 100-ml reaction containing HBS (150 mM NaCl, 20 mM HEPES, pH
7.4, and 5 mM MgCl2). The reaction was allowed to equilibrate at 30 °C
for 5 min. 32P-Labeled NDPK was purified from free [-32P]ATP by two
successive rounds of Microspin G50 columns (Amersham Biosciences,
Piscataway, NJ). 1000 pmol of cpADP was added to the 32P-labeled
NDPK in HBS, and the reaction was carried out for 20 min at 30 °C.
After the reaction, contents were transferred to a Microcon-YM30 (Mil-
lipore, Bedford, MA) and centrifuged at 13,000 rpm for 15 min. With
this procedure we usually obtained 200 Ci of purified [-32P]cyclo-
pentyl-ATP ([-32P]cpATP).
Immunoprecipitations, Kinase Assays, and Two-dimensional Gel
Electrophoresis—100-mm dishes of COS-1 cells (3  106 cells) were
transfected with 6 g of FLAG-ERK2 or FLAG-ERK2-QG and were
allowed to recover overnight. Transfected cells were then serum-
starved for 4–5 h and stimulated with EGF (10 ng/ml) for 10 min. Cells
were washed once with cold phosphate-buffered saline and then lysed
with hypotonic lysis buffer at 4 °C (20 mM HEPES, pH 7.4, 2 mM EGTA,
2 mM MgCl2, 200 mM sodium orthovanadate, 2 g/ml aprotinin, 0.4 mM
microcystin, and 2 mM phenylmethylsulfonyl fluoride). The lysate was
clarified by centrifugation at 13,000 rpm in a microcentrifuge for 20
min. ERK2 or ERK2-QG were immunoprecipitated with anti-FLAG-
M2-agarose beads (Sigma). Immunoprecipitates were washed three
times with hypotonic lysis buffer. Kinase assays were performed with
immunoprecipitated proteins in a 40-l reaction volume containing 25
mM HEPES, pH 7.4, 20 mM magnesium acetate; 1 mM dithiothreitol, 1
mM ATP, or cpATP; and 10 Ci of [-32P]ATP or [-32P]cpATP for 15 min
at 30 °C. Reactions were stopped by addition of an equal volume of 2
SDS-sample buffer and followed by boiling for 5 min. 20 l of these
reactions was analyzed on a 10% SDS-PAGE gel. The resolved proteins
were visualized by the Vorum silver staining protocol (29), and the gel
was autoradiographed by exposing to Kodak Biomax MS film (Eastman
Kodak, Rochester, NY). Remaining samples were clarified of M2-aga-
rose beads by passing through wizard columns (Promega, Madison, WI),
and the proteins were precipitated with 5 volumes of cold acetone.
Precipitated proteins were resuspended in 260 ml of two-dimensional
sample buffer (7 M urea, 2 M thiourea, 4% CHAPS, 2% dithiothreitol,
and 1% IPG buffer (pH 4–7, Amersham Biosciences)) and resolved on
Immobiline Dry Strips (Amersham Biosciences, pH 4–7 linear (L), 13
cm) for 28,000 V-h. The proteins were resolved on 10% SDS-PAGE gels
in the second dimension. Silver staining and autoradiography were
then performed on the gels.
Identification of Novel ERK2 Substrates—Four 150-mm dishes of
COS-1 cells (6  106 cells/dish) transfected with pCDNA3 or FLAG-
ERK2-QG were used. Lysis and immunoprecipitation was performed as
described above. Immunoprecipitated ERK2 and associated proteins
were eluted from the M2-agarose beads with FLAG peptide and ana-
lyzed on 8% SDS-PAGE. Labeled proteins were excised from the gel and
microsequenced using a Finnigan LCQ ion trap mass spectrometer with
a protana nanospray ion source (W. M. Keck Biomedical Mass Spec-
trometry Laboratory, University of Virginia).
In Vitro Kinase Reaction and Phosphoamino Acid Analysis—COS-1
cells were transfected with either FLAG-ERK2, FLAG-ERK2-QG,
pCMV-Tag-EDD (FLAG-EDD), or pCMV-Tag2B. After overnight recov-
ery, cells were serum-starved for 5 h. The cells were stimulated with
EGF (10 ng/ml) for 10 min and lysed in hypotonic lysis buffer, and
FLAG-ERKs were immunoprecipitated with anti-FLAG-M2-agarose
beads. Immunoprecipitated proteins were washed three times with
hypotonic lysis buffer. Immunoprecipitated FLAG-EDD or pCMV-
Tag2B (control) was mixed with immunoprecipitated ERK2 or ERK2-
QG, and kinase reactions were carried out as described above with
[-32P]cpATP for 3 min. For time course kinase reactions, immunopre-
cipitated proteins were eluted from the M2-agarose beads with FLAG
peptide prior to mixing them. Kinase reactions were performed as
mentioned above with [-32P]cpATP. Samples were resolved on 8%
SDS-PAGE gels and transferred to polyvinylidene difluoride mem-
branes followed by autoradiography. Bands corresponding to labeled
EDD were excised, and phosphoamino acid analysis was performed as
described (30).
Metabolic Labeling and Phosphopeptide Analysis—100-mm dishes of
COS-1 cells (3  106 cells) were transfected with 7 g of FLAG-EDD
and 1 g of HA-ERK2 and were allowed to recover overnight. Cells were
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serum-starved for 1 h in Dulbecco’s modified Eagle’s medium followed
by phosphate-free RPMI (Invitrogen) for 1 h. Cultures were then la-
beled in phosphate-free RPMI containing 3 mCi/ml carrier-free 32P
(PerkinElmer Life Sciences) for 3 h followed by stimulation with EGF
(10 ng/ml) for 10 min. Cultures treated with the MEK inhibitor UO126
were incubated with 50 mM inhibitor during the 3-h labeling period and
during EGF stimulation. Cells were lysed in M2 lysis buffer (27) fol-
lowed by immunoprecipitation with anti FLAG-M2-agarose beads. Im-
munoprecipitates were washed five times with M2 lysis buffer, resolved
on 8% SDS-PAGE gels, and transferred to nitrocellulose membranes
followed by autoradiography. Bands corresponding to the labeled EDD
were excised, and tryptic peptides were analyzed by two-dimensional
separation on thin-layer cellulose plates (30).
RESULTS
Based on the crystal structure of ERK2 bound to ATP (31)
and sequence alignment of the ATP binding site of several
protein kinases (18), we observed that both isoleucine 82 and
glutamine 103 are at conserved positions that come into close
contact with the N-6 position of adenine in ATP. We hypothe-
sized that mutation of one or both of these residues to either
alanine or glycine would generate a larger ATP binding pocket
enabling the mutant kinase to accept and utilize ATP analogs
with bulky side groups at the N-6 position. We therefore gen-
erated five ERK2 mutants that contained either single or dou-
ble mutations of these residues to either alanine or glycine. The
five mutants generated were: ERK2 I82A; ERK2 Q103A; ERK2
Q103G; ERK2 I82A/Q103A; and ERK2 I82A/Q103G (Fig. 1A).
All ERK2 constructs encoded an amino-terminal FLAG tag.
We first examined whether mutation of these residues af-
fected the ability of ERK2 to phosphorylate its substrates in
vitro and in vivo. ERK2 or an ERK2 mutant was transfected
into COS-1 cells, and the cells were stimulated with EGF. In
vitro kinase assays were performed with immunoprecipitated
ERK2 and the ERK2 mutants using myelin basic protein
(MBP) and [-32P]ATP as substrates. ERK2 and the mutants
had roughly equivalent levels of kinase activity (Fig. 1B), al-
though alanine mutations at isoleucine 82 somewhat inhibited
ERK2 kinase activity toward MBP. Similar experiments using
serum stimulation or co-transfected mutationally activated
MEK1 (MEK1 S218D/S222D), demonstrated that these mu-
tants could be phosphorylated and activated by activated
MEK1 (data not shown).
To determine if the ERK2 mutants could signal to a physio-
logical ERK2 substrate in vivo, GAL4-Elk1 luciferase assays
were performed. This system utilizes a plasmid containing a
luciferase gene with five GAL4 binding sites in the promoter
and a plasmid encoding a fusion of the DNA-binding domain of
GAL4 and the ERK-responsive transactivation domain of Elk1
(28). MEK1 S218D/S222D was co-transfected to activate both
endogenous and transfected ERK. Co-transfection of ERK2 or
an ERK2 mutant stimulated luciferase expression in a dose-
dependent manner (Fig. 1C). These data demonstrate that
mutation of one or both residues in the ATP binding site of
ERK2 did not substantially affect the localization, substrate
recognition, or kinase activity of ERK2.
We next needed to identify the optimal pairing between an
ATP binding site mutant and an ATP analog. To do this, we
screened each of our ERK mutants with a panel of seven ATP
analogs. We first determined the ability of each analog to
inhibit the capacity of ERK2 or an ERK2 mutant to phospho-
rylate MBP with [-32P]ATP. If an ATP analog was able to
compete with [-32P]ATP for an ERK2 mutant, incorporation of
radiolabeled phosphate into MBP would be inhibited. ERK2 or
an ERK2 mutant was immunoprecipitated from transfected
COS-1 cells stimulated for 10 min with EGF. The FLAG im-
munoprecipitates were aliquoted equally and used in a kinase
reaction containing MBP, 10 M ATP, and 10 Ci of
[-32P]ATP, with or without 100 M ATP analog. The reactions
were resolved on a gel and transferred, and incorporation of 32P
into MBP was quantified by Cerenkov counting. Comparison of
reactions containing an ATP analog (Fig. 2, lanes 2–8 in each
panel) to control reactions without analog (Fig. 2, lane 1 in each
panel) demonstrated that none of the analogs inhibited the
ability of wild-type ERK2 to utilize ATP. By contrast, many of
the ATP analogs had varied abilities to compete with
[-32P]ATP for phosphate incorporation into MBP, suggesting
that some of the ERK2 mutants were able to utilize or at least
bind to the ATP analogs. Mutation of isoleucine 82 alone had
little effect on the susceptibility of ERK2 to inhibition by an
analog. Mutation of glutamine 103 to alanine increased the
susceptibility of ERK2 to inhibition by an analog, whereas
mutation of this residue to glycine had the greatest effect on
the ability of an analog to inhibit 32P incorporation into MBP.
The Q103G mutation (either by itself or in conjunction with the
I82A mutation) demonstrated a significant reduction of 32P
incorporation into MBP when kinase reactions were performed
in the presence of analog. These results suggested that residue
103 of ERK2 was the critical residue in controlling the capacity
of ERK2 to accept an ATP analog with a bulky N-6 substituent.
FIG. 1. ERK2 ATP binding site mutants. A, ERK2 ATP binding
site mutants containing an amino-terminal FLAG tag and mutations at
isoleucine 82 and glutamine 103. B, COS-1 cells were transfected with
ERK2 or an ERK2 mutant. The cells were serum-starved for 5 h before
stimulation with 10 ng/ml EGF for 10 min. FLAG-ERKs were immu-
noprecipitated and tested for their kinase activity toward myelin basic
protein (MBP). C, ERK2 mutants can phosphorylate and activate Elk1
in vivo. COS-1 cells were transfected with 5X Gal4-luciferase, Gal4-
Elk1, MEK1 S218D/S222D, and ERK2 or an ERK2 mutant. ERK2
plasmids were transfected at 5, 25, and 100 ng. The cells were serum-
starved after the transfection and harvested for luciferase assays 24 h
post transfection.
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In particular, a substantial inhibition of 32P incorporation into
MBP by ERK2 Q103G was observed with addition of either
N-6-benzyl-ATP (98.8% inhibition, lane 2, middle panel, right
side), N-6-cyclopentyl-ATP (95.2% inhibition, lane 3, middle
panel, right side), N-6-(3,3-dimethyl)butyl-ATP (98.4% inhibi-
tion, lane 6, middle panel, right side), N-6-(2-phenethyl)-ATP
(97.8% inhibition, lane 7, middle panel, right side), and N-6-(1-
methyl)butyl-ATP (94.1% inhibition, lane 8, middle panel, right
side).
There are two likely explanations for the inhibition of 32P
incorporation into MBP by the addition of excess unlabeled
ATP analog. First, the ATP analog could be utilized as an ATP
source by the mutant ERK2 kinase to phosphorylate MBP, thus
effectively competing with the [-32P]ATP for usage by the
mutant ERK2. Alternatively, the kinase could bind the analog
but not be able to utilize it, thus effectively blocking [-32P]ATP
from the ATP binding site of the kinase. To differentiate be-
tween these two possibilities, we screened ERK2, ERK2-
Q103G, and ERK2-I82A/Q103G for their ability to phosphoryl-
ate GST-Elk1 with either ATP or an ATP analog. The reactions
were resolved on a gel and immunoblotted with an antibody
that specifically recognizes phospho-S383 Elk1, the major site
of phosphorylation by ERK2. Incubation of GST-Elk1 in the
absence of ERK2 did not result in S383 phosphorylation (lane
1). All three ERK2 proteins were able to phosphorylate GST-
Elk1 with normal ATP (Fig. 3, lane 2 in all p-Elk1 panels).
However, wild-type ERK2 could not use any of the ATP analogs
to phosphorylate GST-Elk1 (Fig. 3, top panel, lanes 3–9). These
data support the previous result that none of the analogs could
inhibit wild-type ERK2 from using [-32P]ATP to phosphoryl-
ate MBP.
Conversely, both ERK2-Q103G and ERK2-I82A/Q103G were
able to effectively use several ATP analogs to phosphorylate
GST-Elk1. Overall, ERK2-Q103G appeared to use the analogs
more effectively than ERK2-I82A/Q103G, correlating with the
inhibition assay in Fig. 2. ERK2-Q103G effectively used all of
the ATP analogs tested with the exception of N-6-(p-methyl)-
benzyl-ATP. Although this analog appeared somewhat effec-
tive in the inhibition assay, it was the least efficient of the
seven and was most likely an example of an analog that simply
blocks the ERK2 ATP binding site. Based on the inhibition
assay and the Elk1 phosphorylation assay, we decided to use
ERK2-Q103G (henceforth designated ERK2-QG) along with
cyclopentyl ATP (henceforth designated cpATP) (Fig. 3, middle
panel, lane 4) in our attempts to identify novel ERK2
substrates.
Detection of Direct Substrates of ERK2 with [-32P]cpATP—
To identify relevant substrates of ERK2, one would like to
introduce labeled ATP analog into the live cells. However, cells
are impermeable to ATP, and addition of labeled ATP analog to
digitonin-permeabilized cells results in hydrolysis of the analog
ATP within 1 min (32). Furthermore, the intracellular concen-
tration of ATP is 3 mM (33), making it difficult to achieve analog
concentrations sufficient to compete with ATP for kinases.
Therefore, it was necessary to apply this technique to cell
lysates or fractions. We chose to express the ERK2 and
ERK2-QG (mutant ERK2) in COS-1 cells and then immuno-
precipitate ERKs under non-stringent conditions where we
would expect many ERK-binding proteins to remain associ-
ated. The immunoprecipitates were then used in a kinase re-
action with either [-32P]ATP or [-32P]cpATP. In addition to
ERK2 and ERK2-QG, other co-immunoprecipitated kinases
would be capable of utilizing [-32P]ATP to phosphorylate co-
immunoprecipitated substrates. However, reactions with
FIG. 2. Analog inhibition assay. FLAG-ERK2 plasmids were trans-
fected into COS-1 cells. The cells were serum-starved and stimulated
with 10 ng/ml EGF for 10 min. FLAG-ERKs were immunoprecipitated,
and each was aliquoted into eight sets of duplicate kinase reactions.
Kinase reactions were performed with MBP, 10 M ATP, 10 Ci/reac-
tion [-32P]ATP, without (lane 1) or with (lanes 2–8) 100 M ATP
analog. ATP analogs were: N-6-benzyl ATP (lane 2), N-6-cyclopentyl-
ATP (lane 3), N-6-(p-methyl)benzyl-ATP (lane 4), N-6-(1,3-dimethyl)bu-
tyl-ATP (lane 5), N-6-(3,3-dimethyl)butyl-ATP (lane 6), N-6-(2-phen-
ethyl)-ATP (lane 7), and N-6-(1-methyl)butyl-ATP (lane 8). The
reactions were performed at 30 °C for 10 min, run on a gel, and trans-
ferred to nitrocellulose. MBP bands were excised and quantitated by
Cerenkov counting. The values were normalized to a reaction without
ATP analog (lane 1), which was set at 100%.
FIG. 3. ERK2 phosphorylation of Elk1 with ATP analogs.
FLAG-ERK2 plasmids were transfected into COS-1 cells, and the cells
were serum-starved before stimulation with 10 ng/ml EGF for 10 min.
FLAG-ERKs were immunoprecipitated, aliquoted, and used in kinase
reactions with GST-Elk1 and either 100 mM unlabeled ATP (lane 2) or
100 mM unlabeled ATP analog (lanes 3–9). The reaction in lane 1
contained GST-Elk1 and ATP but no ERK. ATP analogs were: N-6-
benzyl-ATP (lane 3), N-6-cyclopentyl-ATP (lane 4), N-6-(p-methyl)ben-
zyl-ATP (lane 5), N-6-(1,3-dimethyl)butyl-ATP (lane 6), N-6-(3,3-di-
methyl)butyl-ATP (lane 7), N-6-(2-phenethyl)-ATP (lane 8), and N-6-(1-
methyl)butyl-ATP (lane 9). The reactions were incubated at 30 °C for 10
min, resolved on a gel, and transferred to nitrocellulose. The mem-
branes were then immunoblotted with antibodies to phospho-S383
Elk1.
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ERK2-QG and [-32P]cpATP should result in the phosphoryla-
tion of only those proteins that are direct ERK substrates.
Therefore, we should detect fewer radiolabeled substrates in
the reactions with [-32P]cpATP as compared with reactions
with [-32P]ATP.
ERK2 or ERK2-QG from unstimulated or EGF-stimulated
cells were immunoprecipitated, and associated proteins were
labeled in an in vitro kinase reaction using either [-32P]ATP or
[-32P]cpATP. The reactions were resolved on SDS-PAGE, sil-
ver-stained, and subjected to autoradiography (Fig. 4A). ERK2
and ERK2-QG proteins were expressed at similar levels and
were activated efficiently after EGF stimulation (Fig. 4A, silver
stain). Both ERK2 and ERK2-QG used [-32P]ATP very effi-
ciently, generating similar patterns of phosphorylated sub-
strates on SDS-PAGE (Fig. 4A, autoradiogram). Phosphoryla-
tion of substrates in the absence of EGF stimulation was most
likely due to the basal activity of ERK2. There were noticeable
differences in the substrates recognized by ERK2 prior to and
after EGF stimulation (Fig. 4A, autoradiogram; compare lane 1
with 2, lane 3 with 4, and lane 7 with 8). These differences are
probably due to (i) differences in the association of substrates
with ERK2 depending on the phosphorylation status of ERK2;
(ii) dissociation of phosphorylated substrates from ERK2 after
EGF stimulation in vivo; or (iii) prior phosphorylation of the
substrate in vivo during the 10-min EGF stimulation.
When the kinase reactions were performed with [-32P]-
cpATP, there was a marked difference in the pattern of labeled
substrates between reactions with ERK2 and ERK2-QG. Nei-
ther wild-type ERK2 nor its associated proteins could effi-
ciently utilize [-32P]cpATP. The background phosphorylation
with wild-type ERK2 that was detected with [-32P]cpATP was
most likely due to trace contamination with [-32P]ATP
FIG. 4. Detection of ERK2 substrates. FLAG-ERK2 or FLAG-ERK2-QG plasmids were transfected into COS-1 cells. Cells were serum-starved
for 4–5 h followed by stimulation with EGF (10 ng/ml) for 10 min. ERK2 and ERK2-QG were immunoprecipitated, and kinase reactions were
performed with [-32P]ATP or [-32P]cpATP. A, kinase reactions were resolved on 10% SDS-PAGE followed by silver staining and autoradiography.
ATP or cpATP labels on the top indicate kinase reactions carried out with [-32P]ATP or [-32P]cpATP, respectively. ERK2 and dually phospho-
rylated ERK2 (pERK2) are marked by arrows. B, ERK2 in vitro kinase reactions with [-32P]ATP or [-32P]cpATP analyzed on pH 4–7 linear (L)
two-dimensional gels. C, ERK2-QG kinase reactions with [-32P]ATP or [-32P]cpATP analyzed on pH 4–7 L two-dimensional gels.
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(0.1%, data not shown) that occurred when generating
[-32P]cpATP. At this level of electrophoretic resolution, few
differences were detected in the substrates recognized by
ERK2-QG in reactions with [-32P]ATP versus [-32P]cpATP
(Fig. 4A, autoradiogram; compare lanes 3 and 4 with lanes 7
and 8). However, when the resolution of the gel systems was
increased by using two-dimensional gels (Fig. 4, B and C), the
advantages of the analog approach became evident.
ERK2 in vitro kinase reactions with [-32P]ATP or
[-32P]cpATP resolved by two-dimensional gel electrophoresis
are shown in Fig. 4B. These results further demonstrated that
ERK2 and its associated proteins could not utilize
[-32P]cpATP. In vitro kinase reactions using ERK2-QG were
also analyzed on two-dimensional gels (Fig. 4C). Although the
phosphorylation patterns between the [-32P]ATP and the
[-32P]cpATP reactions were somewhat similar, we detected
fewer substrates with [-32P]cpATP. The use of [-32P]cpATP
decreased the overall level of phospho-proteins while enhanc-
ing ERK2-QG-specific phosphorylations. These results clearly
demonstrate the advantage of using [-32P]cpATP for specific
detection of the direct substrates of ERK2.
Identification of Novel ERK2 Substrates—After optimizing
the conditions for the specific detection of direct substrates of
ERK2-QG with [-32P]cpATP, we scaled up the procedure to
detect co-immunoprecipitating substrates by mass spectrome-
try. Proteins co-immunoprecipitating with ERK2-QG were
eluted along with ERK2 from M2 beads with FLAG peptide.
Kinase reactions were then performed with [-32P]cpATP, and
the reactions were resolved on an 8% SDS-PAGE (Fig. 5A). Two
radiolabeled silver-stained bands, one at 80 kDa and the
other at250 kDa, were excised from the lane with a non-EGF-
stimulated (serum-free) sample (Fig. 5A, lane 2) and were
sequenced by mass spectrometry. Eleven peptides (16.3% cov-
erage) corresponding to the ERK2 substrate Rsk1 (34) were
detected in the 80-kDa band. The isolation of a known ERK2
substrate validated our methodology for detecting ERK2 sub-
strates. Mass spectrometry analysis of the 250-kDa band re-
vealed 14 peptides (7% total coverage) corresponding to the E3
ubiquitin ligase EDD (E3 identified by differential display).
EDD is the human homolog of the Drosophila gene hyperplastic
discs and was originally identified as a gene up-regulated in
response to progestin (21). EDD is a 300-kDa protein and
contains a region that has extensive homology to HECT domain
ubiquitin ligases (21).
In a similar experiment we detected a radiolabeled substrate
(250 kDa) that specifically associated with activated
ERK2-QG (Fig. 5B). Mass spectrometric analysis detected 23
peptides (12.4% protein coverage) corresponding to the nucleo-
porin Tpr (translocated promoter region) (35, 24). Tpr is a
nucleoporin that is localized within the nuclear pore complex
and potentially has a role in nuclear protein export (25).
Identical samples were also analyzed on pH 3–10 linear (L)
two-dimensional gels and silver-stained. Most of the radiola-
beled protein spots that were obtained in kinase reactions were
below the detection level, and hence we could not obtain any
sequence data (data not shown). In addition to phosphorylated
proteins, spots corresponding to proteins that were specifically
associated with ERK2, but not phosphorylated, were cored and
sequenced by mass spectrometry. The substrates and ERK2-
associated proteins identified are shown in Table I. Although in
vitro phosphorylation of some of the associated proteins was
not detected, they are still potential substrates in cells. To
further validate our method of labeling ERK2-associated sub-
strates, we attempted to confirm our results with one of the
novel substrates we discovered.
EDD Associates Specifically with ERK2 and ERK1 but Not
MEK1—We chose to reconfirm our results with the novel sub-
strate EDD. For this, ERK2 and ERK2-QG were immunopre-
cipitated from transiently transfected COS-1 cells, resolved on
SDS-PAGE, transferred to nitrocellulose membrane, and
probed with anti-FLAG and anti-EDD antibodies. Similar to
our results in Fig. 5A, EDD associated more strongly with
ERK2 and ERK2-QG in unstimulated versus EGF-stimulated
cells (Fig. 6A, lane 3 versus 4 and lane 5 versus 6). To ensure
that the interaction of EDD with ERK2 was specific, we immu-
noprecipitated ERK2, ERK2-QG, ERK1, and MEK1 from tran-
siently transfected COS-1 cells and probed the blots with anti-
FLAG and anti-EDD antibodies. ERK2, ERK2-QG, and ERK1
interacted with endogenous EDD (Fig. 6B); however, we could
not detect any interaction between MEK1 and EDD. These
results suggest that ERK2 and ERK1, but not MEK1, specifi-
cally associate with EDD.
ERK2-QG Phosphorylates EDD in Vitro—To determine if
ERK2-QG would phosphorylate EDD in vitro, FLAG-ERK2,
FLAG-ERK2-QG, FLAG-EDD, and the vector control were im-
munoprecipitated from transiently transfected COS-1 cells.
Immunoprecipitated ERK2 or ERK2-QG was mixed with im-
FIG. 5. Identification of Rsk1, EDD, and Tpr. pCDNA3.1 or
ERK2-QG plasmids were transfected into COS-1 cells (four 150-mm
dishes/lane, 5–6  106 cells/dish at the time of transfection). Cells were
serum-starved, stimulated with EGF, and lysed with hypotonic lysis
buffer followed by immunoprecipitation with anti-FLAG-M2-agarose
beads. Proteins were eluted with FLAG peptide and kinase reactions
carried out with [-32P]cpATP. A, proteins were resolved on a 8%
SDS-PAGE visualized by silver staining and subjected to autoradiog-
raphy. Bands corresponding to 80-kDa Rsk1 and 250-kDa EDD are
indicated by arrows. B, proteins were resolved on 12% SDS-PAGE,
silver-stained, and subjected to autoradiography. The band correspond-
ing to Tpr is indicated by an arrow.
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munoprecipitated EDD or vector control and in vitro kinase
reactions were carried out with [-32P]cpATP. Because ERK2
does not utilize [-32P]cpATP, we did not detect any phospho-
rylation with vector control or EDD (Fig. 7A; lanes 1 and 2).
ERK2-QG was able to efficiently phosphorylate EDD in vitro
using [-32P]cpATP (Fig. 7A, compare lane 4 versus 3). We then
performed a time course of the in vitro kinase reaction with
ERK2-QG and EDD. Labeling of EDD in the in vitro kinase
reaction reached its peak by 15 min (Fig. 7B, lane 4) with a
slight decrease at 30 min (Fig. 7B, lane 5). EDD has a total of
ten SP and ten TP sites present in 2799 amino acids, and any
of these sites can be potentially phosphorylated by ERK2. To
narrow down the target sites, phosphoamino acid analysis of
in vitro phosphorylated EDD was performed. Our results indi-
cated that the bulk of the phosphorylation was on serine (Fig.
7C), although we did observe very faint phosphorylation of
threonine.
ERK2 Phosphorylates EDD in Vivo—It was apparent that
ERK2 phosphorylated EDD in vitro at one or more serine
residues. However, it was important to know if ERK2 phospho-
rylated EDD in vivo. COS-1 cells transfected with FLAG-EDD
and HA-ERK2 were metabolically labeled with or without EGF
stimulation. In addition, these labeling reactions were carried
out with or without pretreatment of the cells with the MEK1
inhibitor UO126. Two-dimensional tryptic phosphopeptide
maps were analyzed to determine if there were any differences
in the pattern of tryptic peptides with EGF treatment as com-
pared with non-stimulated cells and if these changes were
TABLE I
Substrates and binding partners of ERK2
Proteins Substrate Binds to inactiveERK2
Binds to dually
phosphorylated ERK2
Rsk1 Yes Yes Yesa
EDD Yes Yes Yesa
Tpr Yes No Yes
N-Aminoacylpeptide hydrolase No No Yes
14.3.3 Epsilon No Yes Yes
14.3.3 Zeta/Delta No Yes Yes
a Binding was weaker when compared with that of inactive ERK2.
FIG. 6. EDD associates specifically with ERK2, ERK1 but not
MEK1. A, cells transfected with pCDNA3.1, FLAG-ERK2, and FLAG-
ERK2-QG were serum-starved for 4–5 h followed by stimulation with
EGF. Cells were lysed and proteins were immunoprecipitated with
FLAG-M2-agarose beads, resolved on 10% SDS-PAGE, and immuno-
blotted with anti-FLAG M2 or anti-EDD antibody (21). B, cells trans-
fected with FLAG-ERK2, FLAG-ERK2-QG, FLAG-ERK1, and FLAG-
MEK1 were serum-starved and stimulated with EGF. Cells were lysed
with hypotonic lysis buffer, and proteins were immunoprecipitated with
FLAG-M2-agarose beads, resolved on a SDS-PAGE, transferred onto a
nitrocellulose membrane, and probed with anti-EDD and anti-FLAG
M2 antibodies.
FIG. 7. In vitro labeling and phosphoamino acid analysis. A,
cells were transfected with either FLAG-ERK2, FLAG-ERK2-QG,
FLAG-EDD, or CMV-Tag2B vectors. Cells were serum-starved, and
ERK2 and ERK2-QG were stimulated with EGF (10 ng/ml) for 10 min.
Proteins were immunoprecipitated with FLAG-M2-agarose beads, and
ERK2 or ERK2-QG were mixed with EDD or vector control. Kinase
reactions were carried out with [-32P]cpATP at 30 °C for 3 min. B, time
course of in vitro kinase reactions. Immunoprecipitated FLAG-
ERK2-QG was mixed with FLAG-EDD or vector control (control, C),
and the kinase reactions were carried out for the time indicated above.
In the control kinase reactions were performed for 15 min. C, phos-
phoamino acid analysis of in vitro labeled EDD from time course reac-
tions. p, phosphorylated.
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reversible with UO126 pretreatment. Tryptic peptide maps
obtained under various conditions are shown in Fig. 8A. These
data demonstrate that EDD was phosphorylated on many sites
in unstimulated COS-1 cells (serum-free, Fig. 8A). We detected
the appearance of a new tryptic phospho-peptide with EGF
stimulation (Fig. 8A, shown by an arrow). Pretreatment of cells
with the MEK1 inhibitor UO126 abolished the emergence of
this tryptic phospho-peptide, indicating that the phosphoryla-
tion was either by ERK2 or a downstream kinase. To determine
which of these peptides were due to direct phosphorylation by
ERK2, we compared the tryptic peptide maps of in vivo and in
vitro labeled EDD (Fig. 8B). Our results show that only a few
tryptic peptides were present in both in vivo and in vitro tryptic
peptide maps. These were most likely phosphorylated directly
by ERK2, whereas tryptic peptides that were present only in
labeled EDD in vivo were probably a result of phosphorylation
by other cellular kinases. Interestingly, the tryptic phospho-
peptide that appeared after EGF stimulation was also detected
with in vitro labeling (Fig. 8C, spot 1). Because these tryptic
peptides were analyzed on different TLC plates, to be abso-
lutely sure that the in vitro and in vivo labeled tryptic peptides,
which are migrating at the same positions, were in fact the
same peptides, we eluted them from the plates and re-analyzed
them on the same TLC plate. Peptides 1, 2, and 3 (Fig. 8B) were
eluted from in vivo and in vitro labeled EDD peptide maps and
were spotted on the same TLC plate individually and in con-
cert. Results obtained for the three different peptides are
shown in Fig. 8C. It is evident from our results that peptides
eluted from in vivo and in vitro labeled EDD migrate at the
same position on the TLC plate, indicating that these peptides
were identical. These results demonstrate that tryptic peptides
1, 2, and 3 are directly phosphorylated by ERK2, not a kinase
downstream of ERK2 or any other cellular kinase. Phos-
phoamino acid analysis of in vitro labeled EDD demonstrated
that the bulk of phosphorylation was on serine. The tryptic
phosphopeptide, which appears following EGF stimulation
(Fig. 8A, indicated by arrow, and Fig. 8B, peptide 1) also was
phosphorylated on serine (Fig. 8D), which is in agreement with
the phosphoamino acid analysis of in vitro labeled EDD
(Fig. 7C).
DISCUSSION
To identify novel ERK2 substrates, we adopted the approach
developed by Shokat and coworkers (18) that involves mutating
the ATP binding site of a kinase of interest in a way that allows
it to utilize modified analogs of ATP. Based on this strategy, we
generated mutations in ERK2 at positions 82 and 103 in the
ATP binding site. The mutations did not significantly inhibit
ERK activation in response to growth factors or mutationally
activated MEK. In addition, ERK2 substrate recognition and
signaling were not noticeably affected by the mutations in vitro
or in vivo. Our results demonstrate that glycine mutations at
glutamine 103 were very effective at generating a larger ATP
binding pocket, enabling this mutant, but not wild-type ERK2,
to utilize several ATP analogs to phosphorylate Elk1.
To identify biologically relevant substrates, one would ide-
ally introduce labeled ATP analogs into live or permeabilized
cells. However, because cells are impermeable to ATP analogs
and labeled ATP analogs are quickly hydrolyzed upon addition
to digitonin-permeabilized cells (32) and because of the formi-
dably high intracellular concentrations of ATP (33), the analog
approach requires the use of lysed or fractionated cells. Heter-
ogeneous nuclear ribonucleoprotein K was identified as a sub-
strate of JNK using the ATP analog method in a cell lysate
after the addition of recombinant modified JNK and a
[-32P]ATP analog (20). Addition of large quantities of a kinase
to a cell lysate could result in nonspecific or aberrant phospho-
FIG. 8. Phosphopeptide maps of in vivo and in vitro labeled
EDD. A, phosphopeptide maps of in vivo labeled EDD. Cells were
metabolically labeled with [32P]orthophosphate for 3 h followed by
stimulation with 10 ng/ml EGF for 10 min. For samples with the MEK
inhibitor UO126, 50 M inhibitor was present during the 3-h labeling
and during EGF stimulation. Immunoprecipitated EDD was digested
with trypsin, and the resulting phospho-peptides were mapped by
thin layer chromatography (30). B, comparison of phosphopeptide
maps of in vivo and in vitro labeled EDD. Spots that were at similar
positions on the TLC plates are indicated by numbers and arrows. C,
peptides 1, 2, and 3 from in vivo and in vitro labeled EDD were eluted
and loaded on the same TLC plate separately or together. These
peptides were then mapped as described. D, phosphoamino acid anal-
ysis of EDD tryptic phosphopeptide that appears upon EGF stimula-
tion (in vivo labeled EDD, peptide 1, Fig. 8B). p, phosphorylated.
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rylation of substrates. Therefore, we chose to target only those
substrates that were directly associated with ERK2. In our
work, we expressed the mutant and wild-type ERK2 in vivo
and then immunoprecipitated ERK2 with associated proteins,
with the rationale that this subset of the proteome would more
likely contain biologically relevant ERK2 substrates. These
experiments allowed us to identify ERK substrates in both
unstimulated and mitogen-stimulated cells. In vitro kinase
reactions with wild-type ERK2 and ERK2-QG immunoprecipi-
tates from serum-deprived and EGF-stimulated cells resulted
in similar phosphorylation patterns when [-32P]ATP was
used, demonstrating that the proteins had similar binding
partners and substrate specificity. The use of [-32P]cpATP
with wild-type ERK2 resulted in minimal incorporation of 32P
into proteins, demonstrating that wild-type ERK2 and its as-
sociated proteins could not utilize [-32P]cpATP. However, the
use of [-32P]cpATP with ERK2-QG resulted in robust phos-
phorylation of associated proteins. Interestingly, the labeling
pattern obtained from ERK2-QG revealed some spots that co-
migrated with spots when [-32P]ATP was used, as well as the
disappearance of some spots and the appearance of others. The
disappearance of some labeled spots suggests that these phos-
phorylations were carried out by associated kinases in the
presence of [-32P]ATP. The appearance of new putative sub-
strates in the presence of [-32P]cpATP demonstrates that by
using an ATP analog that can only be utilized by ERK2-QG,
there was an enhancement of the “signal to noise” ratio, pre-
sumably because the ERK2-QG no longer competes with co-
immunoprecipitating kinases for ATP. The increased intensity
of these minor spots strongly supports the advantage of using
the ATP analog system to identify substrates.
Comparison of the labeling pattern of substrates by
ERK2-QG in the unstimulated and stimulated states revealed
differences in labeling of associated proteins. Although some
proteins were labeled under both conditions, we often observed
an enhanced labeling of substrates by ERK2 immunoprecipi-
tated from unstimulated cells. Although at first counterintui-
tive, these results could be due either to an EGF-stimulated
decrease in association of the ERK and the substrate (e.g. note
the decreased association with Rsk1 in Fig. 5A, left panel) or an
increased intracellular phosphorylation of the substrate after
EGF stimulation.
Several ERK binding partners in unstimulated cells, includ-
ing MEK1 and Rsk1, are also ERK substrates. The main ERK2
phosphorylation site on MEK1, Thr-292, is constitutively phos-
phorylated in cells, and phosphorylation is not stimulated by
growth factor treatment (36). Moreover, ERK leaves its MEK
anchor following growth factor stimulation. For both of these
reasons, we are unlikely to detect a significant phosphorylation
of MEK1 in our assay. However, the most prominent phospho-
rylated protein band from unstimulated cells was a 90-kDa
protein that was identified as Rsk1 (34). This served to validate
the assay, demonstrating that the assay allowed identification
of a known ERK substrate.
The nucleoporin Tpr was identified as an ERK2 substrate in
EGF-stimulated cells, but not in unstimulated cells. Tpr local-
izes to the nuclear pore complex. Although the function of Tpr
in this complex is unclear, it may play a role in the nuclear
export of proteins (25). ERK proteins are known to dimerize (6)
and translocate to the nucleus (7, 8) by transport in an active,
Ran-dependent manner, as well as by passive diffusion (37),
although the exact mechanisms remain unknown. The interac-
tion with and phosphorylation of Tpr by ERK following growth
factor stimulation raises intriguing possibilities for both Tpr
function and ERK localization. ERK phosphorylation of Tpr
may play a role in Tpr-regulated transport of proteins out of the
nucleus. Alternatively, ERK association with Tpr may regulate
the nuclear import or export of ERK. The association of ERK2
with Tpr after EGF stimulation, but not in unstimulated cells,
suggests that ERK may interact with Tpr as ERK traverses the
nuclear pore.
Although the ubiquitin ligase EDD was found associated
with ERK2 under both conditions, it was primarily labeled in
kinase reactions from unstimulated cells. EDD was exclusively
found in this phosphorylated band. The absence of phospho-
labeled EDD in reactions from EGF-stimulated cells suggests
that this protein was rapidly phosphorylated by ERK2 in the
cells during the 10 min of EGF stimulation. Indeed, in vivo
orthophosphate labeling experiments revealed the appearance
of a MEK-dependent phospho-peptide in EDD 10 min after
EGF stimulation. In vitro phosphorylation of EDD with
ERK2-QG generated several phospho-peptides that co-mi-
grated with those from the in vivo labeling. In particular, in
vitro phosphorylation of EDD generated a phospho-peptide
that co-migrated with the MEK-dependent in vivo labeled pep-
tide. These in vivo data confirm the conclusion that EDD is a
substrate for ERK2.
Both the presence of a HECT domain in the carboxyl termi-
nus of EDD and the ability of a cysteine residue in this region
to bind ubiquitin suggest that EDD acts as a ubiquitin ligase
and ERK2 phosphorylation of EDD may affect this activity of
EDD. Another possibility is that EDD affects the ubiquitina-
tion of ERK2. ERK2 was recently shown to be ubiquitinated
and degraded in response to osmotic shock induced by sorbitol
treatment (38). Although the ubiquitin ligase that induces ERK
ubiquitination nation is unidentified, the association of EDD
with ERK2 in the basal state may provide a mechanism by
which ubiquitin-mediated degradation of ERK occurs.
In conclusion, we have created a mutant ERK2 kinase that
can utilize an analog of ATP to specifically label ERK2 sub-
strates. These results not only identify two novel ERK sub-
strates, the nucleoporin Tpr and the ubiquitin ligase EDD, but
also provide a framework by which many other ERK substrates
can be identified.
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